id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-0623-0006,FDA,FDA-2016-E-0623,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-07-29T04:00:00Z,2018,7,2018-07-29T04:00:00Z,,2018-07-29T16:43:40Z,,0,0,090000648357ae9c
FDA-2016-E-0623-0005,FDA,FDA-2016-E-0623,"Determination of Regulatory Review Period for Purposes of Patent
Extension; ZERBAXA",Notice,Determinations,2017-11-28T05:00:00Z,2017,11,2017-11-28T05:00:00Z,2018-01-30T04:59:59Z,2017-11-28T16:04:50Z,2017-25682,0,0,0900006482cb6dc0
FDA-2016-E-0623-0004,FDA,FDA-2016-E-0623,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-08-21T04:00:00Z,2017,8,2017-08-21T04:00:00Z,,2017-08-21T16:30:26Z,,0,0,0900006482a671c3
FDA-2016-E-0623-0003,FDA,FDA-2016-E-0623,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-05-11T04:00:00Z,2016,5,2016-05-11T04:00:00Z,,2016-05-11T15:50:55Z,,0,0,0900006481fc408a
FDA-2016-E-0623-0001,FDA,FDA-2016-E-0623,"Patent Extension Application from Oblon and McClelland Maier & Neustadt LLP (on behalf of Astellas Pharma Inc. and Wakunaga Pharmaceutical Co., Ltd.,)",Other,Application,2016-02-24T05:00:00Z,2016,2,2016-02-24T05:00:00Z,,2016-02-24T18:39:21Z,,0,0,0900006481e780f6
FDA-2016-E-0623-0002,FDA,FDA-2016-E-0623,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-02-24T05:00:00Z,2016,2,2016-02-24T05:00:00Z,,2016-02-24T18:39:26Z,,0,0,0900006481e780fa